2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow CureTech Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma CT-011, Rituximab - Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2010-01-01 | 2016-06-03 |
| CT-011 MAb in DLBCL Patients Following ASCT CT-011 - Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse | Phase 2 | Completed | CureTech Ltd | 72 | 2007-10-01 | 2014-09-12 |
Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1)
pidilizumab (2) · Rituximab (1)
United States (2) · India (1) · Israel (1)
Arnon Nagler, MD (1) · Leo I Gordon, MD (1) · Sattva S. Neelapu, MD (1)